Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study

Kikawa, Yuichiro; Kotake, Takeshi; Tsuyuki, Shigeru; Kang, Yookija; Takahara, Sachiko; Fujimoto, Yuri; Yamashiro, Hiroyasu; Yoshibayashi, Hiroshi; Takada, Masahiro; Yasuoka, Rie; Nakatsukasa, Katsuhiko; Yamagami, Keiko; Suwa, Hirofumi; Okuno, Toshitaka; Nakayama, Ichiro; Kato, Takehito; Ogura, Nobuko; Moriguchi, Yoshio; Ishiguro, Hiroshi; Kagimura, Tatsuo; Taguchi, Tetsuya; Sugie, Tomoharu; Toi, Masakazu

doi:10.1007/s12282-022-01357-x

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we developed an adjustment method for the length bias and validated it by demonstrating that the estimated survival time was consistent with the survival data from recent, Japanese randomized clinical trials (the median overall survival for colorectal, breast, and pancreatic cancer was 26.7 months, 2.69 years, and 14.2 months, respectively). [25][26][27] Real-world data obtained from heterogeneous patients in the present study have the potential to enable estimation of the prognostic relevance of uncommon oncogenic variants that cannot be analyzed in standard prospective and retrospective clinical studies.…”

Section: Left Truncation and Right Censoring-adjusted 4 | Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Selection bias due to delayed comprehensive genomic profiling in Japan

et al. 2022

View full text Add to dashboard Cite

Patients with advanced cancer undergo comprehensive genomic profiling in Japan only after treatment options have been exhausted. Patients with a very poor prognosis were not able to undergo profiling tests, resulting in a selection bias called length bias, which makes accurate survival analysis impossible. The actual impact of length bias on the overall survival of patients who have undergone profiling tests is unclear, yet appropriate methods for adjusting for length bias have not been developed. To assess the length bias in overall survival, we established a simulation-based model for length bias adjustment. This study utilized clinicogenomic data of 8813 patients with advanced cancer who underwent profiling tests at hospitals throughout Japan between June 2019 and April 2022. Length bias was estimated by the conditional Kendall τ statistics and was significantly positive for 13 of the 15 cancer subtypes, suggesting a worse prognosis for patients who underwent profiling tests in early timing. The median overall survival time in colorectal, breast, and pancreatic cancer from the initial survival-prolonging chemotherapy with adjustment for length bias was 937

show abstract

Section: Left Truncation and Right Censoring-adjusted 4 | Discussionmentioning

confidence: 99%